Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STIMO-PHARMA: Pharmacological Neuromodulation in SCI
NCT04052776Phase 1Completed
- Sponsor
- Lausanne University Hospital
- Start
- Sep 2020
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of buspirone, levodopa and carbidopa in spinal cord injury (SCI) (4 arms), sponsored by Lausanne University Hospital. Primary endpoints: Rate of AEs/SAEs/Side effects at 4 hours, Changes in blood pressure at 4 hours and 1 more. Started Sep 2020; status: completed.
02
Drugs
buspironelevodopacarbidopa
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT04052776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04052776.